TreeFrog Therapeutics Secures $75m In Series B Financing To Advance A Pipeline Of Stem Cell-Derived Cell Therapies And Deploy Proprietary C-Stem™ Technology In The USA & Japan

Date Published09/13/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name TreeFrog Therapeutics
Parent companyTreeFrog Therapeutics
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
$/year of sales of reshored product or service:83
Country(ies) from which reshored:France
City reshored to:Boston
State(s) reshored to:MA
If relevant, work nearshored to:-
Industry(ies):Medical Equipment & Supplies
Product(s) reshoredbiotech
Find Reshoring Articles